Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309087 · ClinicalTrials.gov registry record
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA
A clinical trial of Lung Cancer, sponsored by Allegro Diagnostics.
- Completed
- Registry status
- 756
- Enrollment target
- 14
- Study locations
NCT01309087: Completed study of Lung Cancer, sponsored by Allegro Diagnostics.
NCT01309087 is a study of Lung Cancer that has completed, run by Allegro Diagnostics. The registered enrollment target is 756 participants, below the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target (19% lower). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01309087, a study of Lung Cancer, has completed, sponsored by Allegro Diagnostics.
- COMPLETED
- Registry status
- 756 participants
- Enrollment target
- 14
- Study locations
Study Summary
The primary objective of this study is to substantiate prediction accuracy(with a tighter 95% confidence interval compared to current diagnostic modalities), of a lung cancer biomarker for risk stratification of patients into high and low risk categories to aid in clinical evaluation of the patient.
Conditions Studied
Study Locations (14)
New York
- New York University - New York
- Columbia University - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- Temple University - Philadelphia
Alabama
- University of Alabama - Birmingham
Georgia
- Georgia Lung Associates - Austell
Indiana
- Indiana University - Indianapolis
Louisiana
- LSU - New Orleans
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01309087
The ClinicalTrials.gov registry entry for NCT01309087 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target (19% lower). The listed sponsor is Allegro Diagnostics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01309087 reports 14 study locations spanning 12 distinct geographic areas - top geographies include New York, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT01309087 about?
NCT01309087 is a clinical study titled "Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA". The primary objective of this study is to substantiate prediction accuracy(with a tighter 95% confidence interval compared to current diagnostic modalities), of a lung cancer biomarker for risk stratification of patients into high and low risk categories to aid in clinical evaluation of the patient.
What is the current status of trial NCT01309087?
This trial is currently completed. The enrollment target is 756 participants. The study started on 2009-01. Estimated completion is 2013-05.
What conditions does trial NCT01309087 study?
This clinical trial studies the following conditions: Lung Cancer.
Who is sponsoring clinical trial NCT01309087?
This trial is sponsored by Allegro Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01309087 being conducted?
This trial has 14 study locations across Alabama, Georgia, Indiana, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.